Ganirelix

FDA approved

Ganirelix is a GnRH antagonist approved by the FDA in 1999 to prevent premature ovulation in women undergoing fertility treatment such as IVF.

At a glance

Where it acts: Sexual & reproductive
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Ganirelix is a synthetic 10-amino acid peptide that competitively blocks pituitary GnRH receptors, rapidly suppressing LH and FSH and preventing a premature LH surge.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Injection site reactions, abdominal pain, headache and vaginal bleeding.

Ovarian hyperstimulation syndrome as part of fertility treatment; hypersensitivity reactions. Contraindicated in pregnancy.

Who Uses Ganirelix

Women undergoing controlled ovarian stimulation for assisted reproduction.